The present invention relates to novel conjugates between polypeptide variants
of protein C and a non-polypeptide moiety, such as PEG or sugar moieties. In particular,
the present invention provides novel protein C conjugates having an increased resistance
to inactivation by e.g. human plasma and 1-antitrypsin. Consequently,
such conjugates have an increased in vivo half-life. Preferred examples include
protein C conjugates, wherein at least one additional in vivo N-glycosylation site
has been introduced. The conjugates of the invention are useful for treating a
variety of diseases, including septic shock.
